July 27, 2021
CellCarta’s poster presents a high-throughput hybrid immunoaffinity LC-MRM based method for quantifying soluble BCMA (sBCMA) in human plasma.
The study demonstrates that sBCMA, a marker for multiple myeloma, can be precisely measured using this method, which overcomes interferences from ligands and therapeutic antibodies. The assay shows high sensitivity, a broad linear range, and robustness against interferences, making it suitable for clinical studies and monitoring treatment response in multiple myeloma patients
As presented in BCMA Summit 2021
View the full posterWebcasts & Webinars
May 2, 2023
Proteomics/Mass Spectrometry
More infoBrochures & Infographics
April 11, 2023
Proteomics/Mass Spectrometry
More info